Therapeutic Area | MeSH |
---|---|
infections | D007239 |
urogenital diseases | D000091642 |
immune system diseases | D007154 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TIVICAY PD | ViiV Healthcare | N-213983 RX | 2020-06-12 | 1 products, RLD, RS |
TIVICAY | ViiV Healthcare | N-204790 RX | 2013-08-12 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TRIUMEQ PD | ViiV Healthcare | N-215413 RX | 2022-03-30 | 1 products, RLD, RS |
TRIUMEQ | ViiV Healthcare | N-205551 RX | 2014-08-22 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
DOVATO | ViiV Healthcare | N-211994 RX | 2019-04-08 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
JULUCA | ViiV Healthcare | N-210192 RX | 2017-11-21 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
dolutegravir | Export only | 2021-03-05 |
dovato | New Drug Application | 2024-04-18 |
juluca | New Drug Application | 2024-04-18 |
tivicay | New Drug Application | 2024-07-18 |
tivicay tivicay pd | New Drug Application | 2024-04-18 |
triumeq | New Drug Application | 2021-03-23 |
triumeq triumeq pd | New Drug Application | 2024-07-08 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
hiv infections | EFO_0000764 | D015658 | B20 |
acquired immunodeficiency syndrome | EFO_0000765 | D000163 | B20 |
hepatitis b | — | D006509 | — |
Expiration | Code | ||
---|---|---|---|
ABACAVIR SULFATE / DOLUTEGRAVIR SODIUM / LAMIVUDINE, TRIUMEQ, VIIV HLTHCARE | |||
2026-12-15 | PED | ||
2026-06-15 | M-294 | ||
ABACAVIR SULFATE / DOLUTEGRAVIR SODIUM / LAMIVUDINE, TRIUMEQ PD, VIIV HLTHCARE | |||
2026-12-15 | PED | ||
2026-06-15 | NPP |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Dolutegravir Sodium / Rilpivirine Hydrochloride, Juluca, Viiv Hlthcare | |||
10426780 | 2031-01-24 | DS, DP | U-257 |
7125879 | 2025-04-21 | DS, DP | U-257 |
Dolutegravir Sodium / Lamivudine, Dovato, Viiv Hlthcare | |||
11234985 | 2031-01-24 | DP | U-257 |
Abacavir Sulfate / Dolutegravir Sodium / Lamivudine, Triumeq, Viiv Hlthcare | |||
9242986 | 2029-12-08 | DS, DP | |
8129385 | 2027-10-05 | DS, DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 53 | 52 | 77 | 49 | 48 | 263 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 33 | 11 | 24 | 15 | 12 | 91 |
Hiv | D006678 | — | O98.7 | 9 | 8 | 11 | 29 | 18 | 72 |
Infections | D007239 | EFO_0000544 | — | 31 | 8 | 21 | 5 | 7 | 70 |
Communicable diseases | D003141 | — | — | 4 | 4 | 12 | 3 | 3 | 24 |
Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 8 | 11 | 4 | 2 | 1 | 21 |
Drug interactions | D004347 | — | — | — | — | — | 3 | 3 | 6 |
Immunologic deficiency syndromes | D007153 | — | D84.9 | — | — | 2 | 4 | — | 6 |
Malaria | D008288 | EFO_0001068 | B54 | 2 | — | — | 3 | — | 5 |
Hiv-1 | D015497 | — | — | — | 1 | 1 | 3 | — | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatitis c | D006526 | — | B19.2 | — | 2 | 2 | — | 1 | 4 |
Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | 1 | 3 | 1 | — | — | 4 |
Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 1 | 1 | 2 | — | — | 4 |
Motor neuron disease | D016472 | EFO_0003782 | G12.2 | — | 1 | 2 | — | — | 3 |
Sclerosis | D012598 | — | — | — | 1 | 2 | — | — | 3 |
Respiratory tract infections | D012141 | — | J06.9 | 1 | 1 | 1 | — | — | 2 |
Pregnancy rate | D018873 | — | — | — | — | 2 | — | — | 2 |
Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | 2 | 1 | — | — | 2 |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | 1 | — | — | 1 |
Hepatitis b | D006509 | — | — | — | 1 | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 16 | 1 | — | — | — | 17 |
Latent tuberculosis | D055985 | — | Z22.7 | 4 | 1 | — | — | — | 4 |
Treatment outcome | D016896 | — | — | — | 2 | — | — | — | 2 |
Disease progression | D018450 | — | — | — | 1 | — | — | 1 | 2 |
Gram-positive bacterial infections | D016908 | — | — | 1 | 1 | — | — | — | 1 |
Htlv-ii infections | D015491 | EFO_1001349 | — | — | 1 | — | — | — | 1 |
Metabolic bone diseases | D001851 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Medication adherence | D055118 | EFO_0006344 | — | 1 | — | — | — | 1 | 2 |
Insulin resistance | D007333 | EFO_0002614 | E88.819 | 1 | — | — | — | — | 1 |
Virus diseases | D014777 | — | B34 | 1 | — | — | — | — | 1 |
Crush injuries | D000071576 | — | T14.8 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | — | — | — | 5 | 5 |
Autism spectrum disorder | D000067877 | — | F84.0 | — | — | — | — | 5 | 5 |
Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 2 | 2 |
Contraception behavior | D003268 | — | — | — | — | — | — | 1 | 1 |
Homosexuality | D006716 | — | — | — | — | — | — | 1 | 1 |
Hiv-2 | D015498 | — | — | — | — | — | — | 1 | 1 |
Persistent infection | D000088562 | — | — | — | — | — | — | 1 | 1 |
Echocardiography | D004452 | — | — | — | — | — | — | 1 | 1 |
Doppler echocardiography | D015150 | — | — | — | — | — | — | 1 | 1 |
Transesophageal echocardiography | D017548 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Dolutegravir |
INN | dolutegravir |
Description | Dolutegravir is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of (4R,12aS)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid with the amino group of 2,4-difluorobenzylamine. Used (as its sodium salt) for treatment of HIV-1. It has a role as a HIV-1 integrase inhibitor. It is a monocarboxylic acid amide, an organic heterotricyclic compound, a secondary carboxamide and a difluorobenzene. It is a conjugate acid of a dolutegravir(1-). |
Classification | Small molecule |
Drug class | antivirals: integrase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21 |
PDB | — |
CAS-ID | 1051375-16-6 |
RxCUI | — |
ChEMBL ID | CHEMBL1229211 |
ChEBI ID | 76010 |
PubChem CID | 54726191 |
DrugBank | DB08930 |
UNII ID | DKO1W9H7M1 (ChemIDplus, GSRS) |